Research & Development

Our key areas of research

Covered an area of 10,000 square meters, complete R&D facilities and advanced testing techniques such as HPLC, GC, NMR (Bruker400MHz), LC-MS, infrared spectrophotometer or UV spectrophotometer to ensure the delivery of top- quality chemicals and meet different needs of our customers.

The well-equipped laboratory and excellent research staff (more than 200 chemists and scientists with over 10 years’ experience in the chemical industry) ensure top-quality products, and we have successfully developed hundreds of new compounds, including API, heterocyclic and benzene derivatives which have been widely used in pharmaceutical, dye, pesticide and other industries.

The support and trust of you power us to constantly develop new compounds to meet the growing demands of the market.

capabilities

API

Commercial List

No.	Molecule	Therapy Area	Dosage Form	USDMF	e-DMF	CEP	BDMF	KDMF	JDMF
1	Cyproterone Acetate	Antiandrogen	Tablet	–	–	ü	–	–	–
2	Levofloxacin Hemihydrate	Antibacterial	Injection; Tablet	ü	–	–	ü	ü	–
3	Linagliptin	Anti-Diabetes	Tablet	–	–	–	–	ü	–
4	Granisetron Hydrochloride	Anti-emetic	Tablet; Injectable, Transdermal Patch	ü	–	ü	ü	–	–
5	Ondanseteron Hydrochloride	Anti-emetic	Injection, Tablet	ü	–	ü	ü	–	–
6	Granisetron Base	Anti-emetic (CINV*)	Tablet, Transdermal Patch	ü	ü	–	–	ü	–
7	Ondanseteron Base	Anti-emetic (CINV*)	Tablet	–	ü	–	–	–	–
8	Fluconazole	Antifungal	Tablet,Injectable,Cream	ü	–	ü	ü	ü	–
9	Terbinafine Hydrochloride	Antifungal	Tablet, cream	ü	–	ü	–	–	–
10	Cetirizine Dihydrochloride	Antihistamine	Tablet, Syrup, capsules	ü	–	ü	–	ü	–
11	Levocetirizine Dihydrochloride	Antihistamine	Tablet; Solution	ü	ü	–	ü	ü	–
12	Desloratidine	Antihistamine	Tablet	–	–	ü	–	–	–
13	Praziquantel	Anti-infective	Tablet	ü	–	ü	–	–	–
14	Celecoxib	Anti-inflammatory	Capsule	ü	–	ü	–	ü	ü
15	Meloxicam	Anti-inflammatory	Tablet, Capsule, Injection	ü	–	ü	–	ü	–
16	Solifenacin succinate	Antimuscarinic	Tablet	ü	–	ü	–	ü	–
17	Irinotecan hydrochloride trihydrate	Antineoplastics	Injection	ü	–	ü	–	ü	–
18	Abacavir Sulphate	Antiretroviral	Tablet, Oral solution	ü	–	ü	–	–	–
19	Atazanavir sulphate	Antiretroviral	Capsule, Tablet, Powder	ü	ü	–	–	–	–
20	Efavirenz	Antiretroviral	Tablet and Capsule	ü	ü	–	–	ü	–
21	Lamivudine	Antiretroviral	Tablet	ü	–	ü	–	ü	–
22	Leflunomide	Antirheumatic	Tablet	ü	–	ü	–	ü	–
23	Entecavir Monohydrate	Antiviral	Tablet	ü	–	ü	–	–	–
24	Famciclovir	Antiviral	Tablet	ü	ü	–	–	–	–
25	Oseltamivir Phosphate	Antiviral	Capsule; Suspension	ü	–	–	–	–	ü
26	Valacyclovir Hydrochloride Dihydrate	Antiviral	Tablet	ü	–	–	–	–	–
27	Valganciclovir Hydrochloride	Antiviral	Tablet, Solution	ü	ü	–	–	–	–
28	Carvedilol	Beta-Blockers, Alpha Activity	Tablet	–	–	ü	–	ü	–
29	Ambrisentan	Cardiovascular	Tablet	ü	ü	–	–	–	–
30	Amlodipine Besylate	Cardiovascular	Tablet	ü	–	ü	ü	ü	ü
31	Amlodipine Mesylate	Cardiovascular	Tablet	ü	ü	–	–	ü	–
32	Anagrelide Hydrochloride	Cardiovascular	Capsule	ü	ü	–	–	ü	–
33	Bosentan Monohydrate	Cardiovascular	Tablet	ü	ü	–	–	–	–
34	Felodipine	Cardiovascular	Tablet	ü	–	ü	–	ü	–
35	Ramipril	Cardiovascular	Tablet and Capsule	ü	–	ü	–	ü	–
36	Trimetazidine Dihydrochloride	Cardiovascular	Tablet	ü	–	ü	ü	ü	–
37	Citalopram Hydrobromide	Central Nervous System	Tablet, Solution	ü	–	ü	ü	–	–
38	Donepezil Hydrochloride	Central Nervous System	Tablet	ü	ü	–	–	ü	–
39	Escitalopram Oxalate	Central Nervous System	Tablet	ü	–	ü	ü	–	–
40	Lamotrigine	Central Nervous System	Tablet	ü	–	ü	–	–	–
41	Pramipexole Dihydrochloride Monohydrate	Central Nervous System	Tablet	ü	–	ü	–	–	–
42	Pregabalin	Central Nervous System	Capsule	ü	–	–	–	ü	–
43	Risperidone	Central Nervous System	Tablet/Oral Solution	ü	–	ü	ü	ü	–
44	Rivastigmine Hydrogen Tartrate	Central Nervous System	Capsule, Trasdermal	ü	–	ü	–	–	–
45	Rizatriptan Benzoate	Central Nervous System	Tablet	ü	–	ü	–	–	–
46	Topiramate	Central Nervous System	Capsule, Tablet	ü	ü	–	ü	ü	–
47	Venlafaxine Hydrochloride	Central Nervous System	Capsule, Tablet	–	–	ü	ü	–	–
48	Alosetron Hydrochloride	Gastrointestinal	Tablet	ü	–	–	–	–	–
49	Esomeprazole Magnesium Dihydrate	Gastrointestinal	Capsule, Tablet, Injection	ü	–	ü	–	ü	–
50	Esomeprazole Magnesium Trihydrate	Gastrointestinal	Capsule	ü	–	ü	–	–	–
51	Lansoprazole	Gastrointestinal	Capsule	–	–	ü	–	–	–
52	Omeprazole	Gastrointestinal	Tablet	ü	–	ü	–	–	–
53	Omeprazole Magnesium	Gastrointestinal	Tablet	–	–	ü	–	–	–
54	Omeprazole Sodium	Gastrointestinal	Tablet,Injection	–	–	ü	ü	–	–
55	Palonosetron Hydrochloride	Gastrointestinal	Injection, Capsule	ü	ü	–	ü	–	–
56	Pantoprazole Sodium Sesquihydrate	Gastrointestinal	Tablet, Injection	ü	–	ü	–	ü	–
57	Cinacalcet Hydrochloride	Hyperparathyroidism	Tablet	ü	–	–	–	–	–
58	Pirfenidone	IPF (Idiopathic Pulmonary Fibrosis)	Tablet, Capsule	ü	–	ü	ü	–	–
59	Deferasirox	Iron chelator	Tablet, Granule	ü	ü	–	–	ü	–
60	Bicalutamide	Nonsteroidal Antiandrogens	Tablet	ü	–	ü	–	–	–
61	Abiraterone Acetate	Oncology	Tablet	ü	–	–	ü	–	ü
62	Erlotinib Hydrochloride	Oncology	Tablet	ü	ü	–	ü	ü	–
63	Etoposide	Oncology	Capsule;Injection	ü	–	ü	–	–	ü
64	Exemestane	Oncology	Tablet	ü	–	ü	ü	–	–
65	Gefitinib	Oncology	Tablet	ü	–	ü	ü	–	–
66	Imatinib Mesylate	Oncology	Tablet	ü	–	ü	ü	ü	–
67	Lenalidomide	Oncology	Capsule	ü	–	–	ü	ü	–
68	Letrozole	Oncology	Tablet	ü	–	ü	–	–	–
69	Pazopanib Hydrochloride	Oncology	Tablet	ü	ü	–	ü	–	–
70	Sorafenib Tosylate	Oncology	Tablet	ü	–		ü	–	–
71	Alendronate Sodium	Osteoporosis	Tablet, Oral solution	ü	–	ü	–	–	–
72	Risedronate Sodium	Osteoporosis	Tablet	ü	–	ü	–	–	ü
73	Albuterol/Salbutamol Sulphate	Respiratory	Aerosol Spray, Oral syrup, Tablet	ü	–	ü	–	–	–
74	Arformoterol Tartrate	Respiratory	Inhalation	ü	–	–	–	–	–
75	Beclomethasone Dipropionate	Respiratory	Aerosal spray	ü	–	ü	–	–	–
76	Budesonide	Respiratory	Capsules, Inhalation Powder, Suspension	ü	–	ü	–	–	–
77	Ciclesonide	Respiratory	Capsule, Inhalation Aerosol	ü	–	ü	–	ü	–
78	Formoterol Fumarate Dihydrate	Respiratory	Inhalation,Aerosol, solution	ü	–	ü	ü	–	–
79	Levalbuterol Hydrochloride	Respiratory	Solution	ü	–	–	–	–	–
80	Mometasone Furoate	Respiratory	Topical,Inhalation Aerosol	ü	–	ü	–	ü	–
81	Mometasone Furoate Monohydrate	Respiratory	Topical,Inhalation Aerosol	ü	–	ü	ü	–	–
82	Salmeterol Xinafoate	Respiratory	Inhalation Aerosol	ü	–	ü	ü	–	–
83	Tiotropium Bromide Monohydrate	Respiratory	Inhalation Aerosol	–	–	ü	ü	–	–
84	Fluticasone Propionate	Respiratory, Dermatology	Inhalation Aerosol, Lotion, cream, ointment	ü	–	ü	ü	–	–
85	Danazol	Urology	Capsule	ü	ü	–	–	–	–
86	Tamsulosin Hydrochloride	Urology	Capsule	–	–	ü	–	–	–
87	Finasteride	Urology,Dermatology	Tablet	ü	–	ü	–	ü	–

Pellets

No	Molecule	Therapy Area
1	Venlafaxine Pellets 32.60%	Central Nervous System
2	Lansoprazole Pellets 8.33%	Gastrointestinal
3	Omeprazole Pellets 8.33%	Gastrointestinal
4	Omeprazole Pellets 8.5%	Gastrointestinal
5	Tamsulosin Pellets 0.4mg	Urology

New DMFs Filed

No	Molecule	Therapy Area
1	Edaravone	Amyotrophic Lateral Sclerosis
2	Empagliflozin	Anti-Diabetic
3	Linagliptin	Anti-Diabetic
4	Efinaconazole	Anti-Fungal
5	Bictegravir Sodium	Anti-HIV
6	Cabotegravir	Anti-HIV
7	Darunavir	Antiretroviral
8	Dolutegravir	Antiretroviral
9	Rilpivirine	Antiretroviral
10	Tenofovir Alafenamide Fumarate	Antiretroviral
11	Rivaroxaban	Anti-Thrombotic
12	Nirmaltrelvir	Antiviral (Covid)
13	Tafamidis	Cardiovascular
14	Vortioxetine	Central Nervous System
15	Difelikefalin	Chronic Kidney disease
16	Sodium Thiosulphate	Cisplatin induced Ototoxicity
17	Nintedanib	Idiopathic Pulmonary Fibrosis
18	Eliglustat	Metabolic Disorder
19	Siponimod Fumarate	Multiple Sclerosis
20	Acalabrutinib	Oncology
21	Dasatinib	Oncology
22	Enzalutamide	Oncology
23	Nilotinib	Oncology
24	Olaparib	Oncology
25	Pomalidomide	Oncology
26	Ticagrelor	Platelet Aggregation Inhibitor
27	Apremilast	Psoriatic Arthritis
28	Fluticasone Furoate	Respiratory
29	Indacaterol	Respiratory
30	Revefenacin	Respiratory
31	Mirabegron	Urological

Under development APIs

No	Molecule	Therapy Area	Stage
1	Edoxaban	Anti-coagulant	Lab Development
2	Tirzepatide	Anti-Diabetes	Lab Development
3	Isavuconazonium	Anti-Fungal	Pre-Validation
4	Rifapentine	Anti-Infectives	Plant validation
5	Ensifentrine	Anti-inflammatory	Lab Development
6	Apixaban	Anti-Thrombotic	Pre-Validation
7	Levoglutamide	Anti-ulcerative	Lab Development
8	Brexpiprazole	CNS	Validation
9	Deucravacitinib	Immunosuppressant	Lab Development
10	Niraparib	Oncology	Lab Development
11	Relugolix	Oncology	Pre-Validation
12	Ruxolitinib	Oncology	Plant Validation
13	Glycopyrronium	Respiratory	Commercial
14	Vilanterol Trifenatate	Respiratory	Plant Validation
15	Abemaciclib	Oncology	Lab development
16	Alectinib	Oncology	Lab development
17	Venetoclax	Oncology	Lab development
18	Lenacapavir	Anti retroviral	Lab development
19	Ivacaftor	Cystic Fibrosis	Lab development
20	Deutavacaftor	Cystic Fibrosis	Lab development
21	Zavagepant	CNS	Lab development
22	Resmetirom	NASH	Lab development
23	Patiromer	Hyperkalemia	Lab development
24	Ixazomib	Oncology	Lab development
25	Etripamil	Cardiovascular	Lab development
26	Terlipressin	Chronic kidney disorders	Lab development
27	Daprodustat	Anemia	Lab development

Crosslinked HA Ophthalmic

Crosslinked Hyaluronic acid

Cross-linking is a chemical strategy that links HA (Hyaluronic acid) molecules to one another,
creating a polymer network.
This process extends the retention properties of HA and decreases its susceptibility to enzymatic
degradation, which ultimately reduces the number of times it needs to be re-applied.

Technology

The cross-link is a process that allows linear hyaluronic acid molecules to be linked together, to obtain new
structures consisting of several hyaluronic acid filaments with a higher molecular weight.
In the cross-linking reaction, two of hyaluronic acid, hyaluronate, derivatives thereof or a mixture thereof form
chemical bond such as ether bond in the present invention between two straight chains without producing by
product, so a cross-linking reaction is theoretically proceeded completely

Applications – Dry Eye Syndrome

Artificial tears – dry eye syndrome

The main limitation of non-cross-linked HA containing tear replacement therapies is the
frequency at which patient need to apply the medication (4 to 6 times daily) in order to
achieve an appropriate response to treatment. Crosslinked HA has more viscoelastic
properties, allowing patients to use only once or twice daily.
In dry eye disease, crosslinked HA as tear supplement seems to provide better ocular
comfort than linear HA.
Crosslinked HA is resistant to degradation
Crosslinked HA has a better bioavailability

Sol-Gel eye drops containing Crosslinked HA

Crosslinked HA showed clarity in simulated tear fluid– mandatory property of an
eye drops
Which is in line with commercially available non-crosslinked HA eye drops
Crosslinked HA is forming a gel/translucent mass at the bottom which is
indicating towards formation of a depot.
Depot formation – reduce frequency of administration

Crosslinked HA API (Ophthalmic)– data sheet

Name of the Test	Specification Criteria	Ophthalmic grade
Description	White or almost white, very hygroscopic powder or fibrous aggregate.	White, fibrous aggregate
Solubility	Sparingly soluble or soluble in water, practically insoluble in acetone and in anhydrous ethanol.	Sparingly soluble in water, practically insoluble in acetone and in anhydrous ethanol
PH	5.0 to 8.5	7.24
Appearance of Solution	Solution S shall be clear and its absorbance at 600 nm is not greater than 0.01.	Solution S is clear and its absorbance at 600 nm is 0.004
Nucleic acids	The absorbance of solution at 260 nm shall be maximum 0.5.	0.2
Chlorides	Maximum 0.5 %	Less than 0.5 %
Loss on drying	Maximum 20.0% w/w	11.0 % w/W
Assay (determine the glucuronic acid content by reaction with carbazole)	95.0 % to 105% (Dried substance)	101.1% on dried substance
BDDE content	Less than 2ppm	Not detected